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Preface 
Jan Malinowski
Dear Reader,
people may be at odds with the criminal 
justice system for a wide range of reasons and their 
deeds can sometimes lead them to prison. A closed 
environment, overcrowding, poor material conditions 
and lack of meaningful activities can have detrimen-
tal effects on prisoners’ physical health and mental 
wellbeing. Enforced idleness and loss of self-esteem 
and self-determination or autonomy can lead to or 
exacerbate behaviours that involve various forms of 
self-harm and risk-taking, including drug use.
For people whose conflict with the law stems 
primarily from their drug use but have not committed 
serious offences, and who also often suffer from men-
tal health problems, referral to appropriate treatment 
may be a preferable option.
People who are sentenced to prison remain 
fully entitled to the internationally recognised right 
to health and—subject only to the deprivation of lib-
erty itself and to the limitations that are inescapable 
for its effective enforcement—all other human rights. 
Recognising that deterioration of health is not a nec-
essary or unavoidable consequence of deprivation of 
liberty, some national administrations have rightly set 
the goal of ensuring that people leave prison in better 
health than when they arrived.
Information gathered in the framework of the 
Pompidou Group’s Criminal Justice and Prison Pro-
gramme confirms that peoples’ health often deterio-
rates in prison, and yet proves that health loss must 
not be regarded as consubstantial to deprivation of 
liberty. Prison offers an opportunity for people—
sometimes their first—to engage with their health 
issues, including drug use. Prisons can, under certain 
conditions, contribute to recovery, enabling people to 
address their problematic drug use and to deal with 
the causes and consequences of drug-taking. 
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Through its Criminal Justice and Prison Pro-
gramme, the Pompidou Group has cooperated with 
national authorities on ways to divert people with 
substance use disorders away from the criminal jus-
tice system and on developing alternatives to impris-
onment, designed to support rather than punish.
Furthermore, we have had the pleasure of 
working with prison administrations that aspire to 
provide the best possible service to their beneficiar-
ies and endeavour to offer human rights-sensitive 
responses to drug problems. The Pompidou Group 
experts have also had the privilege to work with 
excellent health and prison professionals, policy 
makers and civil society representatives committed 
to improving the predicament of people with drug 
problems.
This brochure serves to showcase our work 
in the fields of criminal justice and prisons and pro-
vides examples of our achievements. May it serve as 
a tribute to all those who assist us and help people 
who have drug problems enjoy the highest attain-
able standard of physical and mental health. A very 
warm thank you also to the authorities and donors 
who support these Pompidou Group programmes, in 
particular the European Union and the Government 
of Luxembourg.
A showcase of our work  
in the fields of criminal  
justice and prisons.”
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About us
The Pompidou Group
The Pompidou Group works closely with national policy 
makers and practitioners to develop drug strategies and 
tools that focus on improving health and human rights  
in the criminal justice systems.
T he European Convention on Human Rights pro-tects the rights of over 820 million Europeans. It was drafted by the Council of Europe, the con-
tinent’s leading human rights organisation, in 1950. 
The convention forms the cornerstone of the Council 
of Europe’s work. It also underpins the activities of 
the Cooperation Group to Combat Drug Abuse and 
Illicit Trafficking in Drugs (Pompidou Group) which 
was formed in 1971 on the initiative of the late French 
President Georges Pompidou. The Pompidou Group 
is an intergovernmental body that was incorporated 
into the institutional framework of the Council of 
Europe in 1980.
The core mission of the organisation is to 
tackle drug use and illicit trafficking in drugs by 
supporting the development of effective and evi-
dence-based drug policies in its 38 member states. 
Improving the drug situation in one country bene-
fits all – economically strong member states support 
resource-poorer members of the Pompidou Group 
through targeted interventions and based on demo- 
cratic participation and consensus. Partners of the 
Pompidou Group include non-governmental organi- 
sations, intergovernmental organisations, research 
institutes and networks of professionals. These or-
ganisations make essential contributions to dissem-
ination, networking and good practice sharing on 
national, regional and international levels. The Perma-
nent Correspondents of the Pompidou Group mem-
ber states meet regularly in Strasbourg to discuss 
necessary actions and to present innovative ideas. 
They decide on joint efforts to improve drug policies 
and practices in Europe and beyond – including those 
that are relevant to criminal justice systems.
 A good example of successful international 
cooperation with impact in Europe is the Criminal 
Justice and Prison Programme of the Pompidou 
Group, which aims to develop drug legislation such as 
alternatives to punishment and imprisonment as well 
as treatment services and harm reduction in prisons. 
Drug-dependent persons often fall foul of the law 
because of their drug dependence. Many of them also 
suffer from drug-related, communicable and often 
stigmatising diseases such as HIV or hepatitis C. The 
Secretariat of the Pompidou Group works closely with 
national policy makers and practitioners to develop 
drug strategies and tools that focus on improving 
health and human rights in the criminal justice sys-
tems. This includes interventions that help to reduce 
crime, prison overcrowding and stigmatisation of 
drug-dependent persons.
This brochure introduces the work of the 
Criminal Justice and Prison Programme of the Pompi-
dou Group – by giving a voice to both leading experts 
and people who have survived drug dependence and 
experienced hardship in prison. We hope that this will 
show the way towards human drug policies and prac-
tices in Europe and their impact on crime rates, peo-
ple’s health and human rights.
Furthermore, we present the approach of 
the Pompidou Group to link research, practice and 
policy. The Pompidou Group provides extensive and 
substantial expertise on strengthening the capacity 
of its member and partner states to implement 
domestic criminal justice and drug policy reforms in 
line with Council of Europe standards in the fields 
of human rights, democracy and the rule of law. Pom-
pidou Group actions focus on the development and 
improvement of national legal frameworks (policy) 
and on the enhancement of the professional skills 
(practice) and knowledge (research) of both partners 
and national stakeholders.
The core mission is to  
tackle drug use and illicit 
trafficking in drugs.”
POLICYRESEARCH PRACTICE
The Pompidou Group  
focuses on policy, research 
and practice.”
PILOTING:
Introduce and implement new  
innovative approaches in the  
criminal justice system 
TRAINING OF SPECIALISTS:
Increase knowledge and skills  
of criminal justice staff through 
training and workshops 
SUPERVISION:
Support the work of practitioners  
to sustain the impact of trainings
COOPERATION:
Consult with partners,  
Civil Society Organisations and 
national policy makers
POLICY FORMULATION:
Provide European expertise  
on evidence-based drug policies  
to governments
IMPLEMENTATION:
Support, monitor and evaluate  
the implementation of policies
KNOWLEDGE GENERATION:
Help to understand the drug  
phenomena and effects of drug 
policies
RECOMMENDATIONS:
Translate research findings into 
recommendations that reflect the 
realities of our societies
DISSEMINATION:
Show partners and stakeholders 
what works before drug policies  
are formed
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Interview 
“Treat—not punish!”
Drug expert Prof. Heino Stöver, Frankfurt University of 
Applied Sciences, Germany, tells us how to reduce the risks 
and harm caused by drug use in prisons.
WHAT KIND OF LICIT AND ILLICIT DRUGS ARE USED 
BY PRISONERS IN EUROPE?
Besides tobacco, cannabis is the most com-
monly consumed drug in many prisons. Some stud-
ies have shown that more than 50 % of prisoners use 
cannabis while in prison. Cannabis consumption in 
prisons is also very widespread in Eastern European 
countries. Other drugs such as various opioids, ben-
zodiazepines and alcohol are also frequently used by 
prisoners.
ARE THERE MANY INJECTING DRUG USERS IN 
PRISON?
A far smaller percentage of prisoners report 
that they inject drugs—mainly heroin or other opi-
oids—in prison. According to various studies under-
taken in Europe, between 16 % and 60 % of people 
who injected on the outside continue to inject in 
prison. Although they inject less frequently than out-
side prison, prisoners are far more likely to share in-
jecting equipment than drug injectors in the commu-
nity, and to share this equipment with a significantly 
greater number of people. Many were accustomed 
to easy and anonymous access to sterile injecting 
equipment outside prison and start sharing injecting 
equipment in prison because they lack access to any 
safe equipment there.
WHAT ARE THE MAIN HEALTH RISKS RELATED TO 
DRUG USE IN PRISONS?
Drug use in prisons is characterised by the 
fact that it is forbidden, which means it is a clandes-
tine behaviour. Drugs are being taken in secret and in 
such a way that any detectable sign goes unnoticed. 
Keeping drug use hidden can lead to instances in 
which a person with an overdose is not found in time 
and therefore suffers harm. Each episode of injection 
is far more dangerous than outside prison due to the 
lack of sterile injecting equipment, the high preva-
lence of sharing and the already high prevalence of 
infectious diseases—especially HIV/AIDS and hepati-
tis B/C. Moreover, abscesses can be caused by inject-
ing with dirty injection equipment. Fatally, the health 
risks and any health hazards experienced related to 
drug use cannot generally be discussed in prisons 
with professionals like nurses or doctors, because it 
is an illegal behaviour that attracts disciplinary sanc-
tions, for example loss of remission.
Even after release from prison there are severe 
and life-threatening risks for opioid dependent pris-
oners: Because most of them relapse into heroin use 
after release, the risk of overdose is extremely high. 
The mortality of this group after release is much higher 
compared to other opioid users.
WHY IS ENDURING ABSTINENCE FOR A DRUG- 
DEPENDENT PERSON SUCH A DIFFICULT TASK?
Drug dependence is a chronic, relapsing dis-
order, which means that even after longer periods 
of abstinence relapses might occur if the disorder is 
left untreated. This all means that despite adverse 
effects, drug-dependent prisoners continue their 
habit and try to find ways to satisfy their wish to over-
come the unpleasant state induced by the cessation 
of substance use while in prison. Cravings promote 
continued drug use. Contrary to the perception of 
drug dependence in the general public, this behav-
iour cannot be stopped from one day to the next—it 
needs treatment.
IS IT POSSIBLE TO TREAT SUBSTANCE USE DISOR-
DERS IN PRISONS?
Yes, drug dependence is a treatable condi-
tion—and prisoners’ drug dependence can be treated 
too, in the same way as outside in the community. For 
most dependent people, dependence requires con-
tinued treatments to increase the intervals between 
relapses and diminish their intensity. The ultimate 
goal of drug dependence treatment is to enable indi- 
viduals to manage their substance misuse; for some 
this may mean abstinence, for others harm reduction, 
which means the reduction of medical and social 
adverse effects.
CAN YOU EXPLAIN THE DIFFERENT APPROACHES 
OF HARM REDUCTION AND ABSTINENCE?
Harm reduction and abstinence are two dif-
ferent ways to deal with the consequences of drug 
use: For those not able to live an abstinent life, harm 
reduction measures need to be offered, which means 
preventing the life-threatening and damaging conse-
quences of ongoing drug use. Such measures include 
needle and syringe programmes and overdose pre-
vention programmes.
For those seeking and managing abstinence, 
twelve-step self-help programmes are a non-clinical 
support group and faith-based approach to treating 
dependence, and cognitive-behavioural therapy is 
a professional response to dependence. For opioid- 
dependent prisoners, medication-assisted treatment 
(e. g. with methadone) is a way to keep abstinent from 
other illicit opioids and to lead a functional life.
WHAT SYSTEMIC OR INSTITUTIONAL OBSTACLES 
FOR DRUG PREVENTION AND TREATMENT EXIST IN 
PRISONS?
One of the key obstacles for drug preven-
tion and treatment in prisons is the negation of 
drug use in prison. Numerous studies show that 
many prisoners exhibit ongoing drug use behavi- 
our in most European countries. Once drug use is 
acknowledged in prisons it is often difficult to offer 
the same range and quality of drug treatment ser-
vices as outside. The reasons for this are limited re-
sources and funds and the fragmented manner of 
service delivery by either prison services or outside 
agencies. Moreover, ideological constraints often 
limit the introduction of state-of-the-art interven-
tions, such as medication-assisted treatment. In 
particular, harm reduction measures are often not 
introduced, because this would acknowledge that 
drug use is occurring in prisons, which challenges 
assumptions and is perceived as a threatening sce-
nario by prison managers.
SHOULD PRISONERS BE PUNISHED FOR USING 
DRUGS WHILE IN CUSTODY?
The motto is: Treat—not punish! Drug- 
dependent prisoners should not be punished for 
using drugs while in custody. Drug dependence is 
a severe chronic disorder—and as a medical condi-
tion it should be treated and cannot be punished. 
Drug treatment should be offered to help prisoners 
keep away from drugs and stay clean for longer and 
longer periods of abstinence. This should be done 
by offering individualised and state-of-the-art treat-
ment options, ranging from abstinence to harm 
reduction-oriented interventions. Treatments should 
make use of the expertise of drug users and should 
integrate services from NGOs from the community, 
since these services are perceived as much more 
reliable and confidential.
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Story
A change for the better
Andriy survived 16 years in jail and 30 years of injecting 
drug use. By telling his own personal story, he pleads  
for a nationwide implementation of opioid agonist  
therapy (OAT) in Ukrainian prisons.
W hen I got into jail for the first time, I was 20 years old—and had been using shirka for 5 years.' When Andriy talks about his past, the 
45-year-old man from Kiev identifies his life behind 
bars with the most commonly injected opiate deri- 
vatives used in the Ukraine.
'Shirka' is the almost poetic name for a home-
made and therefore often dirty form of acetylated or 
extracted opium. The drug is weak but cheap—and 
while heroin is unaffordable to many people, shirka 
is widely-used among marginalised and poor drug 
users. Prison inmates inject this homemade opioid 
too. And injecting drug use is disproportionately high 
in Ukraine, according to local experts: in some pris-
ons, about 70 – 75 % of the inmates are injecting drug 
users—suffering the same fate as Andriy.
'In total, I spent 16 years in jail and served 
7 sentences—each of them for drug-related offences,' 
Andriy starts telling his personal story. 'As for my 
case, it was all about 5 cubes of shirka, which our 
drug law enforcement department planted on me. 
Those who end up in jail got there for 'storage' of 
drugs, but it doesn’t make sense – how can you 
use but not store?' Andriy speaks emotionally, when 
he questions the Ukrainian drug legislation and 
prison system. Data by International HIV/AIDS Alli-
ance shows that in 2011 every sixth person convic- 
ted in Ukraine was convicted of drug crimes—this 
means 25,457 people out of a total of 154,356. And 
more than 55 % of these drug crimes involved pos-
session of drugs for personal use. 
Unbearable personal tragedies
The criminalisation of drug use is a policy that 
also leads to unintended negative effects—putting 
convicted users at a higher risk of getting infected with 
HIV or other diseases. In the first representative study 
in Ukraine, conducted in 13 Ukrainian prisons, 19.4 % 
of prisoners were identified as HIV positive. This is 12 
times higher than in the general Ukrainian population 
and strongly connected to drug use within prison. 
According to a study involving HIV-infected inmates, 
56.8 % reported injecting drugs in prison, 74.1 % of 
whom shared equipment, with an average of 4.43 
users per needle.
These figures are consistent with the per-
sonal experiences of Andriy, who blames the lack of 
clean needles and syringes as being responsible for 
the high infection rate in prisons: 'There were lots of 
different stories, some people died in my arms, while 
I managed to save some from overdoses both in and 
outside jail. One might say I did not get infected with 
HIV thanks only to my inner will. After all, many peo-
ple in jail cannot afford a clean syringe, so twenty 
people sometimes share one to inject.'
Andriy's report is full of personal tragedies, 
caused by the difficult conditions within the Ukrain-
ian prison system: 'I remember when I had to literally 
take away the needle from a guy who was going to 
inject after his mate who had HIV. And this guy, he 
never even thanked me but said something like it was 
none of my business. There were also other stories 
when cops gave prisoners syringes which they got 
from those sick with tuberculosis to share and inject. 
It is true, it’s not my sick imagination!'
A change for the better
But despite these traumatic experiences, 
Andriy has not given up hope that the conditions in 
prison may change for the better: 'Last Sunday, I was at 
the funeral of a man I knew, who died of a methadone 
overdose in prison. If I had gone back to jail, I would 
have died as many of my friends did. The peers of my 
age who are still alive are living normal lives thanks to 
the OAT programme. Many of them found jobs and 
started families.' OAT is an abbreviation for Opioid 
Agonist Therapy—a highly effective measure for treat-
ing dependencies and preventing harm from opioid 
use. Andriy is convinced that the OAT programme 
saved his life—and would protect prison inmates from 
getting infected with HIV or overdosing. 'Without OAT, 
I would be back in jail now. There is an urgent need to 
introduce OAT in jails—OAT could save lives.' 
And Andriy has solid arguments why OAT 
should be established in Ukrainian prisons nation-
wide: 'Jails are in desperate need of OAT. It will bring 
down the risk of getting infected with HIV and hepa- 
titis. When I served my last sentence, four people I 
knew well got infected with HIV and three with hepa- 
titis C through injecting drugs. It happens because 
they share one syringe for injections and they don’t 
have enough time to at least boil the homemade 
drug because prison staff may come any minute, so 
they have to do everything quickly … Many people 
take the syringe even if they know that their mates 
have HIV, because their cravings are stronger.'
Harm reduction and rehabilitation
But OAT is not only an effective instrument of 
harm reduction and prevention, it also supports so-
cial rehabilitation. 'People in the programme will stop 
thinking about getting drugs or finding money to pay 
for them. Instead, they will focus on being released on 
parole. OAT brings only positive changes into the lives 
of opioid-dependent people. It brings people back to 
life, helps them to re-socialise and therefore it has 
benefits for the state too!'
And Andriy himself is the greatest example 
of successful social rehabilitation. 'I earn my living 
with my vape shop. My friend and business partner is 
also on OAT—he has been receiving buprenorphine 
for six years now. Isn't that great? Two former drug 
addicts and repeat offenders have legal jobs, make a 
positive contribution to society and pay taxes!' Andriy 
grins and continues: 'Now I live a different life—a life 
I could have never imagined before. My family now 
treats me with trust and respect. Thanks to OAT.'
My family now  
treats me with trust  
and respect.”
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Interview 
„Tangible results in Europe.“
Our Teamwork
Robert Teltzrow is the principal project consultant for the 
Pompidou Group and is responsible for the implementation 
of the Group's criminal justice and prison projects. 
WHAT IS THE MAIN OBJECTIVE OF YOUR PROJECTS?
We want to improve health services for 
drug users in contact with the criminal justice sys-
tem which also means ensuring that they can fully 
enjoy their human rights. That is the main objective 
of the Pompidou Group’s Criminal Justice and Prison 
Programme—that is, what we all want to achieve. 
This includes supporting opiate agonist therapy and 
drug-free treatment services such as Therapeutic 
Communities. We also help governments to develop 
policies and rehabilitative measures of treating, edu-
cating or reintegrating drug users as alternatives to 
conviction or punishment.
AND WHAT HAVE YOU ACHIEVED SINCE THE START 
OF THE PROJECTS? 
We have achieved tangible results in many 
European countries. In Georgia we developed a road 
map in cooperation with the government for intro-
ducing a law on alternatives to punishment. Togeth-
er with the Department of Penitentiary Institutions 
of the Moldovan Ministry of Justice we refurbished 
prison wards which will accommodate Therapeutic 
Communities. In Ukraine, we introduced drug treat-
ment and prevention tools in juvenile prisons. Each 
country has its specific needs and challenges—and 
together with our partners on site we develop im-
pact-oriented strategies that are already producing 
improvements.
COULD YOU BRIEFLY SUMMARISE THE APPROACH 
OF THE POMPIDOU GROUP?
The Pompidou Group links drug policy, 
practice and research—while focusing on the real-
ities of local implementation of drug programmes. 
Our approach is therefore based on practical expe-
rience and on scientific findings. In our projects we 
train doctors, prison managers and decision makers 
and work closely with researchers who generate cut-
ting-edge knowledge on a whole range of drug use 
and trafficking problems. In this way we contribute 
to harmonising drug policies in Europe in many fields 
of work including public health, criminal justice and 
human rights.
THE POMPIDOU GROUP SUPPORTS AGONIST THE-
RAPY AND DRUG-FREE TREATMENT PROGRAMMES. 
AREN’T THESE TWO COMPETING PHILOSOPHIES: 
GETTING PEOPLE CLEAN ON THE ONE HAND AND 
PROVIDING THEM WITH REPLACEMENT DRUGS ON 
THE OTHER?
These are two complementary approaches 
opening more possibilities: We should give choices 
to persons who have problems with drugs—that’s 
what a comprehensive system of medical, psycho-
logical and social services for drug-dependent per-
sons should ensure. An effective and people-centred 
drug treatment system should comprise pharma-
cologically assisted treatment, like opiate agonist 
therapy, harm reduction, and drug-free approach-
es such as therapeutic communities. Agonist treat-
ment is an effective and important tool in the fight 
against HIV and hepatitis C, and can help opiate 
dependent drug users to stop or at least reduce their 
use of illicit drugs. A drug-free treatment on the other 
hand helps drug users who are not dependent on 
opiates and want to stop using or overusing drugs. 
Irrespective of this question, we learned one crucial 
lesson: drug treatment services are especially effec-
tive if they are embedded in the general health and 
social care system.
T he Pompidou Group team takes the plans and decisions made by the member states and turns them into reality. We form the Secretariat of the 
Pompidou Group, which is based in the Agora build-
ing of the Council of Europe in Strasbourg. Each team 
member works on specific tasks and projects and to-
gether we ensure the coherence of our work. For ex-
ample, the Criminal Justice and Prison Programme is 
closely linked with other areas of the work activities of 
the Pompidou Group such as prevention, treatment 
and law enforcement. In this way, we ensure an en-
during transfer of knowledge and an integrated ap-
proach based on evidence and cutting-edge science. 
Regular team meetings create synergies to gain more 
impact in the different projects and build the team 
spirit needed for the challenging and important work 
of each team member to succeed.
If you want to learn more about the program- 
mes, watch our documentary about harm reduc- 
tion in Moldovan prisons. 
www.youtube.com/
watch?v=In61XFnAmx8
Team meeting of the Pompidou Group Secretariat in Strasbourg. From right to left: Jan Malinowski, Thomas Kattau, 
Elena Hedoux, Audrey Tumulty, Florence Mansons, Florence Mabileau and Robert Teltzrow.
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Alternatives  
to Punishment
Every sixth prisoner in Europe is a drug user. The prison  
system is overstretched because it has to deal with drug- 
related offences and their rising costs. But there are effective 
alternatives to punishment and imprisonment.
R educing crime and making society a safer place while saving taxpayers’ money—that’s the greatest contribution to society criminal 
justice systems can make in the current context of 
financial contraints in Europe. The evidence about 
the costs, effects and unintended consequences 
of drug control policies becomes increasingly avail-
able—and puts pressure on policy makers to find 
more effective responses for people who are in 
trouble with the law because of drug-related of-
fences. Key driving factors of this development are 
the increasing costs of court procedures related 
to the large number of people with substance use 
disorders kept in prison. In addition, studies show 
that sanctions and prison sentences are often coun-
terproductive in treating addiction and preventing 
drug users from reoffending after release. The costs 
for society explode because of the number of drug 
users with problematic use patterns in prison. This 
marked increase can be seen in too many European 
countries.
Currently, every sixth prisoner in Europe is a 
drug user. And many are imprisoned for non-violent 
and minor offences, often acquisitive crime. Conse-
quently, drug policy experts around the world rec-
ommend developing alternatives to punishment and 
coercive sanctions for drug users such as education, 
treatment, aftercare and social reintegration.
Europe has a rich experience with various 
legal mechanisms that address drug-related offences 
such as arrest referral, suspension of proceedings, 
specialised drug courts and treatment instead of pun-
ishment. Unfortunately, policy makers do not always 
have access to information as well as comparable and 
practical analyses about promising approaches that 
exist in other European countries. In order to reform 
their criminal justice systems in line with European 
values they rely on expert opinions and fora to discuss 
state-of-the-art interventions that have been success-
ful in other parts of Europe.
The Pompidou Group studies the drug phe-
nomenon and assists governments around Europe 
to develop new policies on alternatives to punish-
ment and imprisonment. More recently, the Group 
organised activities in Malta and Georgia, which are 
considering reforming their criminal justice systems 
after a careful assessment of the risks and opportu-
nities that come along with introducing new laws. In 
the framework of its Criminal Justice and Prison pro-
jects the Pompidou Group conducts comparative 
research on European jurisdictions, invites interna-
tional experts to present European good practices 
and organises exchanges of experience for policy 
makers and drug policy experts.
Today we know that criminal justice reforms 
can lead to cost reduction and a more effective treat-
ment of drug users.
G ood drug policies save lives, improve health and support the wellbeing of our societies. Europe allows us to draw on a wealth of expe-
rience and drug policies in the form of national action 
plans and strategies, as well the instruments provided 
by the Pompidou Group, the Council of Europe, the 
EMCDDA and the European Commission—reflecting 
the diversity of the drug situations in the different 
countries. But why do some drug policies reach their 
goals while others fail? Drug-related research pro-
vides answers and evidence for governments before 
drug policies are formed and finalised. Policy-makers 
need research messages that are clear cut, unambig-
uous and relevant to their work and priorities. Good 
research, however, reflects the complexities of prac-
tice. Hence, the Pompidou Group works together with 
researchers, policy makers and practitioners to trans-
late complex research findings into comprehensible 
messages which reflect the realities and diversity of 
our societies. The link between policy and research is 
one of the strong points of the Criminal Justice and 
Prisons Programme—studies conducted by the Pom-
pidou Group provide orientation for policy makers. 
‘Drug treatment systems in 10 European countries’ of-
fers governments an international comparison of drug 
treatments. The ‘Comparative study on alternatives to 
imprisonment for drug-dependent people’ show gov-
ernments hands-on models for practical and effective 
interventions in their prison systems.
Research helps governments to change their 
policies: to foster effective, viable and accepted ac-
tions and to prevent, treat and counteract the spread 
of substance use disorders and crime. Policy makers 
can really make a difference. Repressive policies can 
lead to prison overcrowding. However, policies that 
follow a rehabilitative approach that emphasises 
treatment over punishment can help drug-depend-
ent people to remain or become again active and 
responsible in supporting their livelihood and con-
tribute to our societies.
Its possible: cost and  
crime reduction through 
drug treatment.”
Policy and Research 
Effective management through 
research, good practice and  
innovative policies
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Interview 
“We can make a difference!”
Igor Guja, Deputy Director General of the Department of 
Penitentiary Institutions of the Republic of Moldova discusses 
the progressive approach for tackling drug use problems  
in Moldovan prisons.
MR. GUJA, PLEASE TELL US YOUR WAY OF DEALING 
WITH DRUG DEPENDENCE AND DRUG TREATMENT.
There is a direct link between the consump-
tion of narcotics, including opiates, and criminal behav-
iour. Drug users often commit crimes to buy drugs for 
personal consumption. Many of these people continue 
to use narcotics in prison after being convicted. Moldo-
va is progressive in tackling drug use problems because 
it provides a comprehensive system of services and 
treatment programmes for drug-dependent prisoners, 
including needle and syringe exchange programmes 
and opioid agonist therapy (OAT) with methadone.
DEPENDENCE
Tackling drug dependence in a prison requires 
an entire package of measures—and implementing 
this package requires teamwork.
WHICH RESPONSIBILITIES DO YOU DELEGATE TO 
YOUR STAFF?
You see, when it comes to the treatment of 
drug users in our prisons the main goal of our prison 
staff is to prevent the spread of HIV and hepatitis. Pris-
on doctors, psychologists, social workers and security 
staff work together to prevent criminal behaviours 
and drug use. In Moldova we have effective instru-
ments to reduce health risks for staff and prisoners: 
opioid-dependent prisoners can receive methadone 
for treatment and in addition, the DPI provides sterile 
syringes to drug-dependent inmates.
WHAT ARE THE EFFECTS OF THE OPIATE AGONIST 
THERAPY (OAT) PROGRAMME—BOTH TO PERSONS IN 
TREATMENT AND TO THE INSTITUTION AS A WHOLE?
The prisoners’ health, the prison system and 
society as a whole—everyone benefits from an ad-
equate and evidence-based organisation of OAT in 
prisons. Research has proved that continuous OAT 
can prevent overdoses. And compared to detoxifi-
cation programmes, OAT shows better adherence to 
drug treatment programmes and antiretroviral thera-
py (for HIV)—also after release. We also see that drug 
users who are enrolled in OAT are less likely to commit 
further criminal offences and are easier to reintegrate 
into society compared to other inmates. Methadone 
treatment is also beneficial for the security of the pris-
on because it reduces the demand for illicit drugs. This 
improves the lives of both prisoners and prison staff. 
AND ARE THERE ANY RISKS?
I would strongly recommend OAT to all my 
colleagues in other member states, even though—or 
precisely because—I am very aware of security con-
cerns. It is essential to identify and address security 
issues and to prevent the diversion of methadone in 
the prison by having the methadone treatment im-
plemented by a multidisciplinary team of health care 
professionals, social workers and security staff.
TOGETHER WITH THE POMPIDOU GROUP OF THE 
COUNCIL OF EUROPE, THE DPI REFURBISHED A 
PRISON WARD TO ACCOMMODATE A THERAPEUTIC 
COMMUNITY. WHAT DO YOU EXPECT FROM THIS 
ENDEAVOUR?
This is a very important step because it will 
substantially contribute to the social reintegration of 
former drug users. Drug treatment services are more 
effective when they are combined with psycho-social 
support. If we provide psycho-social support in com-
bination with replacement therapy we can bring 
about behavioural and emotional changes. We bene- 
fit hugely from the partnership with the Pompidou 
Group. We can make a difference if we adopt new and 
successful approaches.
Practice
Empowerment through 
education, workshops and 
training 
H uman rights and health rights are not realised through law alone. To build a dignified crimi-nal justice system, a society needs well-skilled 
practitioners to coherently safeguard and foster the 
rights of its citizens—including those who are im-
prisoned. The Pompidou Group implements state-
of-the-art training programmes and workshops to 
provide practitioners with cutting-edge knowledge 
and skills to effect reforms and progress in the crimi- 
nal justice and prison field. A good example of this 
targeted capacity building is the Therapeutic Com-
munity project in the Republic of Moldova. Over the 
course of two years, Pompidou Group experts from 
Norway and Romania trained Moldovan prison doc-
tors, psychologists and social workers on how to run 
a prison-based Therapeutic Community (TC). The TC 
opens its doors in 2017 in a newly refurbished area of 
Pruncul prison in Chisinau.
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I uliana Curea does not have long to drive to visit one of her major projects. From her office at the Depart-ment of Penitentiary Institutions it takes just a few 
minutes to get to Penitentiary No. 9 in Pruncul, a mu-
nicipality of Moldova’s capital, Chisinau. 'For sure, it’s 
like entering a different world’, Iuliana reveals while 
standing in front of the prison entrance. ‘But the funda-
mental principles of our society—the rule of law and 
human rights—should apply especially in prison.’
Iuliana is the Head of Psychological Services, 
35 years old and highly motivated to improve drug 
treatment services in Moldovan prisons. She is su-
pervising the building of a Therapeutic Community 
within the prison, a measure that contributes to the 
implementation of a coherent drug treatment sys-
tem in Moldovan prisons. ‘TCs are another effective 
treatment option for drug-dependent prisoners’, says 
Iuliana Curea. ‘It is new in our prison system and will 
complement other health, social and psychological 
services that we offer in order to help prisoners who 
are dependent on drugs.'
It started with harm reduction
Moldova is recognised as an example of good 
practice due to its successful HIV programmes. In the 
early 2000s Moldova introduced Opiate Agonist Ther-
apy (OAT) and a Needle and Syringe Exchange Pro-
gramme (NSP) in its prisons. As a consequence, HIV 
among prisoners dropped by over 50 percent. This 
was expected, because research consistently shows 
that OAT and NSP are effective in curbing the spread 
of HIV and other blood-borne diseases in the commu-
nity and in prisons.
The top leadership in Moldova’s penitentiary 
system acknowledges that—like in other prison sys-
tems around the world—drug control measures can 
only reduce illegal drugs entering prisons and not 
fully prevent the drug trade in their facilities. Injecting 
drug use continues behind bars and drug-depend-
ent prisoners are at high risk of infecting themselves 
with HIV or hepatitis C if they share injection equip-
ment with other inmates. Providing clean needles 
and syringes to prisoners was a both pragmatic and 
successful solution that was introduced in Moldova 
in 1999: The Department of Penitentiary Institutions 
expanded the range of drug prevention and treat-
ment services in prisons and introduced OAT. From 
this date, opiate-dependent prisoners could receive 
liquid methadone, a medication that reduces crav-
ings for drugs and consequently the risk of infections 
through injecting. In order to increase the impact and 
coverage of these programmes, the Pompidou Group 
organised a series of workshops and conferences in 
Moldova, in cooperation with the United Nations Office 
on Drugs and Crime (UNODC). The professional skills 
of the health care staff at the Department of Peniten- 
tiary Institutions improved. In 2013 Moldova joined 
the Pompidou Group as a full member state, thanks 
to its consistent support to Moldova and the country’s 
strong commitment to contribute to international 
drug policy cooperation.
It continues with Therapeutic Communities 
But this was just the beginning. During a 
workshop in Chisinau in 2013, the participants—pris-
on doctors and psychologists—concluded that harm 
reduction alone would not cater for the needs of all 
drug-dependent persons in prisons. The impetus for 
the initiative came directly from the medical staff 
working in the prisons. Eduard Verejan, chief doctor 
at Prison No. 9, explains: ‘Those prisoners who are not 
injecting drug users or dependent on opioids, as well 
as prisoners who are not eligible for OAT, need alter-
native drug treatment services. We cannot give meth-
adone to them.
Iuliana Adam adds: 'At this point it was clear 
to me that our psychologists and social workers need 
to learn more about psychological counselling and 
drug-free treatment programmes. During a study visit 
organised by the Pompidou Group I learned about 
the Romanian experience with Therapeutic Commu-
nities in prisons. I knew immediately that we should 
have the same project in Moldova.’ 
With support from the Pompidou Group and the EU
So from her own experience Iuliana Curea can 
only recommend any kind of transnational knowledge 
transfer—and is especially thankful for the support of 
the Pompidou Group: ‘We organised a meeting with 
Robert Teltzrow from the Pompidou Group and Rune 
Hafstad, an expert from the Norwegian TC “Phoenix 
Haga”, who helped to implement TCs in Romanian 
prisons. We agreed that we would make use of the 
Romanian experience to build our own prison-based 
TC,' Iuliana says with a smile on her lips. ‘Finally we 
developed a programme, “made in Moldova”.’ 
Additional support came from the European 
Union: in 2014 the EU agreed to finance the creation 
of one or two TCs in Moldovan prisons. Luxembourg, 
a member state of the Pompidou Group, also provid-
ed a voluntary contribution in support of the project. 
In early 2015, the Department of Penitentiary Institu-
tions signed a Memorandum of Understanding with 
the Pompidou Group which formed the cornerstone 
of today’s fruitful cooperation. In the two years since 
then, German, Norwegian and Romanian experts have 
travelled regularly to Moldova to train 25 psycholo-
gists, doctors and social workers who will run the TC. 
Story
Made in Moldova
A visit in prison – to the first prison-based Therapeutic  
Community project in Moldova.
In 2013 Moldova joined  
the Pompidou Group as a 
full member state.”
It’s like entering a new world. 
And human rights should  
apply especially in prison. ”
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Outlook
D rug policies and the criminal justice system must be made to help drug-dependent peo-ple like Andriy (see page 8 – 9) to live a healthy 
and productive life. They should also provide a legal 
and institutional framework that creates opportuni-
ties for professionals like prison psychologist Iuliana 
Curea (see page 16 –18) who want to enhance their 
skills and knowledge to implement services that 
help prisoners to rehabilitate and reintegrate into 
our societies. Europe’s criminal justice systems and 
drug polices are moving away from a punitive idea 
that criminalises drug-dependent people towards a 
rehabilitative approach that focuses on drug treat-
ment and harm reduction (see page 6 –7). Faced with 
evidence about the limited success, side effects and 
costs of repressive drug policies, policy and decision 
makers increasingly embrace approaches that are of-
ten more cost-effective and offer alternatives to pun-
ishment of drug users who are in trouble with the law 
(see page 13). In order to keep up with these inter-
national developments and evidence-based innova-
tions in the field of public health and drug policy, it 
makes sense that national governments, civil society 
organisations and researchers in Europe and beyond 
move closer together to exchange good experiences, 
knowledge and expertise. The Pompidou Group, 
together with its partners assumes its responsibility 
to improve drug policies in Europe by providing sup-
port and a platform for its member states to exchange 
good practice in such important fields as criminal 
justice and prison policies.
The Pompidou Group provides  
support and a platform to 
exchange good practice.”What is a Therapeutic  
Community?
A Therapeutic Community is a well-developed metho- 
dology for treating drug addiction. It is a methodolo-
gy that has been introduced worldwide and modified 
to suit local cultures and traditions. A Therapeutic 
Community consists of a wide range of behavioural 
and psychological interventions to help the resident 
change from a dependent lifestyle to a life without 
drugs. The Therapeutic Community represents a 
social microcosm, a miniature society in which resi-
dents live together 24/7 and experience all aspects 
of life’s challenges in a safe environment. The client 
has an opportunity to investigate the challenges 
and to change his or her perception and behaviour 
in response to these challenges. Therapeutic Com-
munities have been proven to be an effective metho- 
dology for treating substance use disorders when 
supplemented by a rehabilitation-oriented aftercare 
programme. Some of the basic elements of a Thera-
peutic Community are:
–  Mutual self-help
–  Common philosophy
–  Common values
–  A daily schedule
Training with international experts
In interactive trainings, the trainees learned 
how to manage a TC: from the understanding that 
substance use disorders (SUDs) have a chronic and 
often relapsing nature to the different stages of re-
covery, they acquired the skills to bring about cog-
nitive change through clinical interventions in the 
framework of the TC.
Iuliana sums up the results of the workshops: 
’It was an intensive training course consisting of five 
workshops during which our participants learned a 
lot about the theory and practice of TCs. We did role 
plays and simulation exercises that helped our pro-
fessional staff to imagine how it will be when the TC 
starts working.’ As the visit to the prison comes to an 
end, there is time for one more question: ‘How do you 
feel shortly before the kick-off?’ ‘I think now every 
one of us is looking forward to the opening of the 
TC. We are a little bit anxious about how we do, but 
our experts will assist us during the first phase of the 
project.’ she admits and confidently adds: ‘So it will 
be a great success—and a major opportunity for the 
drug-dependent inmates in our prisons!’
While the prison doors are closing, Iuliana 
Curea says goodbye. She is very satisfied with the 
visit and the current state of the project. Moldova’s 
first prison-based Therapeutic Community will open 
its doors in 2017.
–  Clear responsibilities
–  Hierarchic structure
–  Role modelling
–  Clear expectations

